What's Going On With Johnson & Johnson Stock Friday?

Benzinga
2025.08.29 11:38
portai
I'm PortAI, I can summarize articles.

Nipocalimab 聯合療法在 2a 期試驗中未顯示出比抗 TNFα 治療更好的療效。強生公司終止了類風濕關節炎研究，但對 nipocalimab 的潛在市場價值超過 50 億美元。這個勞動節享受 60% 的折扣，獲取一年的快速、可操作的交易提醒

Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.